Home
Drugs
Azacitidine
Clinical Trials

Clinical Trials Related to Azacitidine

Related studies linked through entity extraction aliases.

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Status: RECRUITING
Phase: PHASE1/PHASE2

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Status: WITHDRAWN
Phase: PHASE1

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Status: COMPLETED
Phase: PHASE3

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Status: RECRUITING
Phase: PHASE1/PHASE2

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Status: RECRUITING
Phase: PHASE2

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status: COMPLETED
Phase: PHASE1

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Status: COMPLETED
Phase: PHASE3

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Status: TERMINATED
Phase: PHASE3

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Status: UNKNOWN
Phase: PHASE2

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status: RECRUITING
Phase: PHASE1

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Status: RECRUITING
Phase: PHASE2

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Status: COMPLETED
Phase: PHASE1

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status: COMPLETED
Phase: PHASE1